Based on the incidences of cancer, metastasis, and cancers previously reported to be associated with ferroptosis, we first verified that low levels of LASS2 were associated with poor clinical features and poor prognosis in patients with thyroid, breast, or liver cancer. This evidence concerns the gene CERS2 and liver cancer.